KCT0000584
Completed
未知
A randomized, open-label, multiple-dose, crossover study to investigate the pharmacokinetic drug interaction between rosuvastatin and telmisartan in healthy volunteer
ConditionsNot Applicable
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not Applicable
- Sponsor
- Yuhan
- Enrollment
- 48
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy male and female aged 20 to 50 with a body mass index(BMI) between 19 and 27 kg/m2
- •2\. Acceptable medical history, physical examination, laboratory tests and EKG, during screening
- •3\. Provision of signed written informed consent
Exclusion Criteria
- •1\.History of and clinically significant disease
- •2\.Sitting blood pressure meeting the following criteria at screening:
- •150 \= systolic blood pressure \=90 (mmHg) and
- •95 \= diastolic blood pressure \= 50 (mmHg) amd
- •100 \= Heart rate \= 40
- •3\. A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs.
- •4\. Administration of other investigational products within 90 days prior to the first dosing.
- •5\. Administration of herbal medicine within 30 days or administration of ethical drugs within 14 days or administration of over\-the\-counter (OTC) drugs within 7 days prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
- •6\.Have AST(SGOT) or/and ALT(SGPT) \> 3 times of normal upper limit at the time of screening
- •7\. Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A randomized, open-label, multiple-dose, crossover study to compare the safety, pharmacokinetics and pharmacodynamics of DHNP-2001B to RD-02 in healthy adult subjectsNot ApplicableKCT0008390DaehanNupharm44
Completed
Not Applicable
Targeting healthy adult volunteers. The subjects are assigned to sequence 1 or sequence 2 through randomization. Once assigned to the sequence, repeated oral administration of the Test IP(DHNP-2001A) and the Reference IP(RD-01) in that order. The test is divided into Period 1 and 2, and in the case of Period 2 administration, the opposite of Period 1 administration is administered. This clinical trial is designed open-label and aims to compare pharmacokinetic and pharmacokinetic characteristics and safety.Not ApplicableKCT0008519DaehanNupharm44
Active, not recruiting
Not Applicable
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR capsule 32 mg and Dilatrend® tablet 25 mgNot ApplicableKCT0000787Chong Kun Dang48
Completed
Not Applicable
A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Linagliptin after oral administration in healthy male volunteerEndocrine, nutritional and metabolic diseaseKCT0001326Dong Hwa Pharm12
Completed
Not Applicable
A Randomized, open-label, multiple-dose, crossover phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Metformin after oral administration in healthy male volunteerEndocrine, nutritional and metabolic diseaseKCT0001386Dong Hwa Pharm12